As shown in Fig. 6E,F, neutralizing endogenous IL-13 or IL-4 by activated CD4+ T cells with anti-IL-13 mAb or anti-IL-4 mAb both resulted in an enhanced IL-17A production and ROR-γt mRNA expression in RA patients. This evidence concerns the gene IL17A and rheumatoid arthritis.